{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T21:21:50Z","timestamp":1794345710540,"version":"4.9.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.annonc.2026.10.001","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T23:48:58Z","timestamp":1791503338000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sofetabart mipitecan, an antibody\u2013drug conjugate targeting folate receptor alpha, in high-grade ovarian cancer: results from the first-in-human phase I study"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2472-8306","authenticated-orcid":false,"given":"I.","family":"Ray-Coquard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.M.","family":"O\u2019Malley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Oaknin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Madariaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6327-0176","authenticated-orcid":false,"given":"N.","family":"Lakhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.B.","family":"McKean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Perez-Fidalgo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Okera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5807-8458","authenticated-orcid":false,"given":"T.","family":"Koyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5273-0561","authenticated-orcid":false,"given":"J.S.","family":"Frenel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1781-2518","authenticated-orcid":false,"given":"G.","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7436-0891","authenticated-orcid":false,"given":"M.R.","family":"Khawaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.C.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0981-0598","authenticated-orcid":false,"given":"D.","family":"Lorusso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7786-4371","authenticated-orcid":false,"given":"V.","family":"Pilla Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.M.","family":"Speck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Gilligan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Szpurka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Manvelyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2300-4935","authenticated-orcid":false,"given":"Y.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Avsar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2621-8553","authenticated-orcid":false,"given":"C.F.","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Sachdeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Kyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Pothuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.annonc.2026.10.001_bib1","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/s41416-022-02031-x","article-title":"Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes","volume":"128","author":"Bax","year":"2023","journal-title":"Br J Cancer"},{"issue":"32","key":"10.1016\/j.annonc.2026.10.001_bib2","doi-asserted-by":"crossref","first-page":"52553","DOI":"10.18632\/oncotarget.9651","article-title":"Targeting folate receptor alpha for cancer treatment","volume":"7","author":"Cheung","year":"2016","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.annonc.2026.10.001_bib3","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41571-020-0339-5","article-title":"Exploiting the folate receptor alpha in oncology","volume":"17","author":"Scaranti","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2026.10.001_bib4","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2022.33.e82","article-title":"High expression of folate receptor alpha is associated with poor prognosis in patients with cervical cancer","volume":"33","author":"Yazaki","year":"2022","journal-title":"J Gynecol Oncol"},{"key":"10.1016\/j.annonc.2026.10.001_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1254532","article-title":"Therapeutic strategies targeting folate receptor alpha for ovarian cancer","volume":"14","author":"Mai","year":"2023","journal-title":"Front Immunol"},{"issue":"13","key":"10.1016\/j.annonc.2026.10.001_bib6","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1200\/JCO.22.01900","article-title":"Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study","volume":"41","author":"Matulonis","year":"2023","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.annonc.2026.10.001_bib7","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab soravtansine in FRalpha-positive, platinum-resistant ovarian cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.annonc.2026.10.001_bib9","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1158\/1538-7445.AM2023-1544","article-title":"Abstract 1544: MBK-103, a potent novel conjugation platform-based antibody-drug conjugate, changing therapeutic options in folate receptor alpha positive cancer patients","volume":"83","author":"Viricel","year":"2023","journal-title":"Cancer Res"},{"issue":"suppl 16","key":"10.1016\/j.annonc.2026.10.001_bib10","article-title":"Initial results from a first-in-human phase 1 study of LY4170156, an ADC targeting folate receptor alpha (FR\u03b1), in advanced ovarian cancer and other solid tumors","volume":"43","author":"Ray-Coquard","year":"2025","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2026.10.001_bib30","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2026.10.001_bib12","article-title":"Model-informed phase 3 dose selection for antibody-drug conjugate (ADC) sofetabart mipitecan (Sofe-M): first prospective application of a clinical utility index (CUI)","volume":"1016P","author":"Frenel","year":"2026","journal-title":"ESMO"},{"issue":"22","key":"10.1016\/j.annonc.2026.10.001_bib13","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","article-title":"Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer","volume":"391","author":"Bardia","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.annonc.2026.10.001_bib14","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1200\/JCO-25-02142","article-title":"Ifinatamab deruxtecan in patients with extensive-stage small cell lung cancer: primary analysis of the phase II IDeate-Lung01 Trial","volume":"44","author":"Rudin","year":"2026","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.annonc.2026.10.001_bib15","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2026.10.001_bib16","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1200\/JCO-25-01210","article-title":"Atezolizumab with bevacizumab and nonplatinum chemotherapy for recurrent ovarian cancer: final results from the placebo-controlled AGO-OVAR 2.29\/ENGOT-ov34 phase III trial","volume":"44","author":"Harter","year":"2026","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.annonc.2026.10.001_bib17","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1093\/annonc\/mds203","article-title":"The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane\/platinum-based therapy","volume":"23","author":"Hanker","year":"2012","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2026.10.001_bib18","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ejogrb.2012.10.003","article-title":"Advanced (>second) line chemotherapy in the treatment of patients with recurrent epithelial ovarian cancer","volume":"166","author":"Bruchim","year":"2013","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"1","key":"10.1016\/j.annonc.2026.10.001_bib19","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/IGC.0b013e3182049273","article-title":"Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube","volume":"21","author":"Griffiths","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.annonc.2026.10.001_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/S0923-7534(20)34331-3","article-title":"Weekly paclitaxel (PAC), pegylated liposomal doxorubicin (PLD) or topotecan (TOP)\u00b1bevacizumab (BEV) in platinum (PT)-resistant recurrent ovarian cancer (OC): analysis by chemotherapy (CT) cohort in the GCIG AURELIA randomised phase III trial","volume":"23","author":"Poveda","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2026.10.001_bib21","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ygyno.2024.10.013","article-title":"Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha-expressing recurrent ovarian cancer: an integrated safety summary","volume":"191","author":"Moore","year":"2024","journal-title":"Gynecol Oncol"},{"issue":"8","key":"10.1016\/j.annonc.2026.10.001_bib22","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1136\/ijgc-2024-005401","article-title":"Mirvetuximab soravtansine in folate receptor alpha (FRalpha)-high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial","volume":"34","author":"Coleman","year":"2024","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1016\/j.annonc.2026.10.001_bib23","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.annonc.2026.10.001_bib24","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1038\/s41467-025-58266-8","article-title":"Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)","volume":"16","author":"Tsao","year":"2025","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.annonc.2026.10.001_bib25","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41523-025-00829-5","article-title":"Antibody-drug conjugates in breast cancer: mechanisms of resistance and future therapeutic perspectives","volume":"11","author":"Valle","year":"2025","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.annonc.2026.10.001_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104979","article-title":"Bystander effect in antibody-drug conjugates: navigating the fine line in tumor heterogeneity","volume":"216","author":"Wang","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"issue":"10538","key":"10.1016\/j.annonc.2026.10.001_bib27","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S0140-6736(26)00602-1","article-title":"Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65\/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study","volume":"407","author":"Colombo","year":"2026","journal-title":"Lancet"},{"issue":"10496","key":"10.1016\/j.annonc.2026.10.001_bib28","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1016\/S0140-6736(25)01040-2","article-title":"Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial","volume":"405","author":"Olawaiye","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2026.10.001_bib29","article-title":"FRAmework-01: a three-part phase 3 study of sofetabart mipitecan (Sofe-M) in platinum-resistant ovarian cancer (PROC), and Sofe-M plus bevacizumab (Bev) in platinum-sensitive ovarian cancer (PSOC)","author":"O\u2019Cearbhaill","year":"2026","journal-title":"ESMO"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426067815?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426067815?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T20:32:27Z","timestamp":1794342747000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753426067815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":28,"alternative-id":["S0923753426067815"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2026.10.001","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sofetabart mipitecan, an antibody\u2013drug conjugate targeting folate receptor alpha, in high-grade ovarian cancer: results from the first-in-human phase I study","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2026.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}